World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials

M. Boers; P. Tugwell; D. T. Felson; P. L.C.M. Van Riel; J. R. Kirwan; J. S. Smolen; N. Khaltaev

World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials

M. Boers^*
, P. Tugwell
, D. T. Felson
, P. L.C.M. Van Riel
, J. R. Kirwan
, J. S. Smolen
, N. Khaltaev

^*Corresponding author for this work

Elizabeth Blackwell Institute for Health Research

Research output: Contribution to journal › Article (Academic Journal) › peer-review

326 Citations (Scopus)

Abstract

The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.

Original language	English
Pages (from-to)	86-89
Number of pages	4
Journal	Journal of Rheumatology
Volume	21
Issue number	SUPPL. 41
Publication status	Published - 15 Sept 1994

Keywords

Clinical trials
Endpoints
RA

Handle.net

Persistent link

Cite this

@article{d901b22ac0c84bd5b6276fb40ab46db5,

title = "World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials",

abstract = "The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.",

keywords = "Clinical trials, Endpoints, RA",

author = "M. Boers and P. Tugwell and Felson, \{D. T.\} and \{Van Riel\}, \{P. L.C.M.\} and Kirwan, \{J. R.\} and Smolen, \{J. S.\} and N. Khaltaev",

year = "1994",

month = sep,

day = "15",

language = "English",

volume = "21",

pages = "86--89",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "SUPPL. 41",

}

World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. / Boers, M.; Tugwell, P.; Felson, D. T. et al.
In: Journal of Rheumatology, Vol. 21, No. SUPPL. 41, 15.09.1994, p. 86-89.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials

AU - Boers, M.

AU - Tugwell, P.

AU - Felson, D. T.

AU - Van Riel, P. L.C.M.

AU - Kirwan, J. R.

AU - Smolen, J. S.

AU - Khaltaev, N.

PY - 1994/9/15

Y1 - 1994/9/15

N2 - The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.

AB - The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.

KW - Clinical trials

KW - Endpoints

KW - RA

UR - https://www.scopus.com/pages/publications/0027936586

M3 - Article (Academic Journal)

C2 - 7799394

AN - SCOPUS:0027936586

SN - 0315-162X

VL - 21

SP - 86

EP - 89

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - SUPPL. 41

ER -

World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials

Abstract

Keywords

Handle.net

Other files and links

Fingerprint

Cite this